Dominant contribution of malignant endothelial cells to endotheliopoiesis in chronic myeloid leukemia.

Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, P.R. China.
Experimental hematology (Impact Factor: 3.11). 11/2008; 37(1):87-91. DOI: 10.1016/j.exphem.2008.08.009
Source: PubMed

ABSTRACT Although it has been well-established that hemangioblasts are present in chronic myeloid leukemia (CML) and contribute to both malignant hematopoiesis and endotheliopoiesis, the real contribution of CML-derived endothelial cells to endotheliopoiesis in CML patients has never been evaluated. The current study sought to determine CML-derived endotheliopoiesis in patients with CML.
Endothelial cells were isolated from the bone marrow or peripheral blood of six newly diagnosed CML patients using an immunomagnetic approach. The resulting endothelial cells were immediately subjected to fluorescence in situ hybridization analysis to determine BCR-ABL-positive endothelial cells.
The purity of isolated endothelial cells was 94.47% +/- 2.37%. In bone marrow, the BCR-ABL-positive endothelial cells accounted for 70.8% +/- 10.7% of total freshly isolated endothelial cells. In peripheral blood, however, the BCR-ABL-positive endothelial cells accounted for only 20.8% +/- 9.8% of isolated endothelial cells.
The present data demonstrate a dominant contribution of CML-derived endothelial cells to endotheliopoiesis in newly diagnosed CML, and provide the rationale for targeting hemangioblasts and angiogenesis in management of CML.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Acute lymphoblastic leukemia (ALL) is a heterogeneous disorder, and primary drug resistance and relapse are thought to be the main causes for treatment failure in ALL patients. For these refractory or relapsed patients, there is an increasing demand to identify novel therapeutic approaches, which will highly rely on the use of xenotransplantation models in translational research. Given the critical role that the spleen plays in the hematopoiesis and lymphopoiesis in adult mice, intrasplenic inoculation of ALL cells into immunodeficient mice may represent a feasible route for leukemic xenotransplantation. In the present study, engraftments via intrasplenic inoculation in anti-mCD122 mAb conditioned NOD/SCID mice were achieved in 5 out of 11 cases, and the engrafted cells reconstituted a complete leukemic phenotype. The engrafted cells sustained the self-renewal capacity of leukemia-initiating cells as tested by serial xenotransplantation and can be used for evaluation of antileukemic drugs. These data suggest that the combination of intrasplenic inoculation and the targeted depletion of CD122 (+) cells could provide a novel approach for the xenotransplantation of ALL cells in NOD/SCID mice. Furthermore, this model can be used for stem cell research, long-term analysis of engraftment kinetics and in vivo drug tests.
    Cancer biology & therapy 10/2012; 13(12):1158-64. · 3.29 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Angiogenesis is increasingly recognized as an important prognosticator associated with the progression of lymphoma and as an attractive target for novel modalities. We report a previously unrecognized mechanism by which lymphoma endothelium facilitates the growth and dissemination of lymphoma by interacting with circulated T cells and suppresses the activation of CD4(+) T cells. Global gene expression profiles of microdissected endothelium from lymphoma and reactive lymph nodes revealed that T cell immunoglobulin and mucin domain-containing molecule 3 (Tim-3) was preferentially expressed in lymphoma-derived endothelial cells (ECs). Clinically, the level of Tim-3 in B cell lymphoma endothelium was closely correlated to both dissemination and poor prognosis. In vitro, Tim-3(+) ECs modulated T cell response to lymphoma surrogate antigens by suppressing activation of CD4(+) T lymphocytes through the activation of the interleukin-6-STAT3 pathway, inhibiting Th1 polarization, and providing protective immunity. In a lymphoma mouse model, Tim-3-expressing ECs promoted the onset, growth, and dissemination of lymphoma by inhibiting activation of CD4(+) T cells and Th1 polarization. Our findings strongly argue that the lymphoma endothelium is not only a vessel system but also a functional barrier facilitating the establishment of lymphoma immune tolerance. These findings highlight a novel molecular mechanism that is a potential target for enhancing the efficacy of tumor immunotherapy and controlling metastatic diseases.
    Journal of Experimental Medicine 02/2010; 207(3):505-20. · 13.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this study we investigated whether neoplastic transformation occurring in Philadelphia (Ph)-negative myeloproliferative neoplasms (MPNs) could involve also the endothelial cell compartment. We evaluated the level of endothelial colony-forming cells (E-CFCs) in 42 patients (15 with polycythemia vera, 12 with essential thrombocythemia, and 15 with primary myelofibrosis). All patients had 1 molecular abnormality (JAK2(V617F) or MPL(W515K) mutations, SOCS gene hypermethylation, clonal pattern of growth) detectable in their granulocytes. The growth of colonies was obtained in 22 patients and, among them, patients with primary myelofibrosis exhibited the highest level of E-CFCs. We found that E-CFCs exhibited no molecular abnormalities in12 patients, had SOCS gene hypermethylation, were polyclonal at human androgen receptor analysis in 5 patients, and resulted in JAK2(V617F) mutated and clonal in 5 additional patients, all experiencing thrombotic complications. On the whole, patients with altered E-CFCs required antiproliferative therapy more frequently than patients with normal E-CFCs. Moreover JAK2(V617F)-positive E-CFCs showed signal transducer and activator of transcription 5 and 3 phosphorylation rates higher than E-CFCs isolated from healthy persons and patients with MPN without molecular abnormalities. Finally, JAK2(V617F)-positive E-CFCs exhibited a high proficiency to adhere to normal mononuclear cells. This study highlights a novel mechanism underlying the thrombophilia observed in MPN.
    Blood 01/2011; 117(9):2700-7. · 9.78 Impact Factor